M. Goebeler

Hermann Einsele, Carsten Reinhardt, Thomas Burmeister, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

H. Einsele, L. Kanz, A. Mackensen, 2011 .

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m2/d Is Tolerable and Highly Effective

H. Einsele, P. Kufer, G. Zugmaier, 2010 .

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

H. Einsele, P. Kufer, P. Baeuerle, 2008 .

Clinical activity of the anti-CD19 bite (R) blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL): Interim results of a phase II study

H. Einsele, P. Kufer, G. Zugmaier, 2011 .

S2010 Outcome and Quality of Life Favor a Conservative Treatment of Patients with Primary Gastric Nhl's. Results of a Prospective Randomized Study

W. Fischbach, M. Goebeler, S. Schramm, 2008 .

Differences in migration inhibitory factor production by C57Bl/6 and BALB/c mice in allergic and irritant contact dermatitis.

J. Roth, M. Goebeler, C. Sorg, 1990, International archives of allergy and applied immunology.

Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL.

H. Einsele, G. Zugmaier, H. Horst, 2012 .

Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.

M. Stauch, V. Heinemann, D. Oruzio, 2011, European journal of cancer.

Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE®) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

M. Pfreundschuh, M. Libicher, R. Bargou, 2013 .

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

H. Einsele, P. Kufer, P. Baeuerle, 2009 .

Early clinical trial unit tumor board: a real-world experience in a national cancer network

V. Heinemann, M. von Bergwelt-Baildon, M. Subklewe, 2023, Journal of Cancer Research and Clinical Oncology.

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

T. Brümmendorf, F. Finkernagel, M. Huber, 2017, Leukemia.

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

P. Kufer, G. Zugmaier, C. Brandl, 2016 .

Tumor-promoting Versus Tumor-antagonizing Roles of &ggr;&dgr; T Cells in Cancer Immunotherapy: Results From a Prospective Phase I/II Trial

J. Becker, H. Einsele, B. Kimmel, 2012, Journal of immunotherapy.

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma with the Bispecific T-Cell Engager (BiTE®) Antibody Construct Blinatumomab: Primary Analysis Results from an Open-Label, Phase 2 Study

M. Pfreundschuh, M. Libicher, G. Hess, 2014 .

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

H. Döhner, U. Jäger, M. Hallek, 2017, Leukemia.